Challenging and Defending Patents in the Country's Largest Venue ― the PTAB
- 11:30 a.m.
Life sciences companies are increasingly using IPRs and PGRs as part of their strategy to bring drugs to market. This trend exists not only for generic drugs and biosimilars, but also for new innovator drugs that may implicate competitors' patents. During this session, director Eldora L. Ellison, Ph.D., will focus on issues that challengers and patent owners must take into consideration in bringing or defending against post-grant challenges before the U.S. Patent Trial and Appeal Board.